Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04064060
Registration number
NCT04064060
Ethics application status
Date submitted
9/08/2019
Date registered
21/08/2019
Titles & IDs
Public title
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Query!
Scientific title
A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Query!
Secondary ID [1]
0
0
U1111-1235-8123
Query!
Secondary ID [2]
0
0
ACE-536-LTFU-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Myelodysplastic Syndromes (MDS)
0
0
Query!
Beta-thalassemia
0
0
Query!
Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Luspatercept
Experimental: ACE-536 - Luspatercept will be administered as a subcutaneous (SC) injection to participants by the study staff at the clinical site and administration will be documented in the subject's source record.
Treatment: Drugs: Luspatercept
Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-ß (TGF-ß) superfamily. Members of the TGF-ß superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Adverse Events (AEs)
Query!
Assessment method [1]
0
0
Type, frequency, severity of AEs, relationship of treatment emergent adverse events to luspatercept
Query!
Timepoint [1]
0
0
From enrollment until at least 42 Day Safety Follow-up Phase or EOS (Approximately 5 years).
Query!
Primary outcome [2]
0
0
Number of participants progressing to high/very high risk MDS or AML.
Query!
Assessment method [2]
0
0
Progression to high/very high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) (MDS and myelofibrosis \[MF\] only).
Query!
Timepoint [2]
0
0
Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Query!
Primary outcome [3]
0
0
Percentage of participants progressing to high/very high risk MDS or AML
Query!
Assessment method [3]
0
0
Progression to high/very high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) (MDS and myelofibrosis \[MF\] only)
Query!
Timepoint [3]
0
0
Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Query!
Primary outcome [4]
0
0
Number of participants developing other malignancies/pre-malignancies
Query!
Assessment method [4]
0
0
Development of other malignancies/pre-malignancies
Query!
Timepoint [4]
0
0
Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Query!
Primary outcome [5]
0
0
Percentage of participants developing other malignancies/pre-malignancies
Query!
Assessment method [5]
0
0
Development of other malignancies/pre-malignancies
Query!
Timepoint [5]
0
0
Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Query!
Secondary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Time from date of randomization until death from any cause
Query!
Timepoint [1]
0
0
Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Query!
Secondary outcome [2]
0
0
Number of participants developing treatment emergent extramedullary hematopoiesis (EMH) masses
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Query!
Secondary outcome [3]
0
0
Percentage of participants developing treatment emergent EMH masses
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
Query!
Eligibility
Key inclusion criteria
Participants must meet all the following criteria to be enrolled in this study:
1. Participant is = 18 years at the time of signing the informed consent form (ICF).
2. Participant is willing and able to adhere to the study visit schedule and other protocol requirements.
3. Participant has been participating in a luspatercept trial and continues to fulfill all the requirements of the parent protocol and the participant has been either:
1. Assigned to luspatercept treatment, continues to receive clinical benefit in the opinion of the investigator and should continue to receive luspatercept treatment, OR
2. Assigned to placebo arm in the parent protocol (at the time of unblinding or in follow-up) and should cross over to luspatercept treatment, OR
3. Assigned to the Follow-up Phase of the parent protocol, previously treated with luspatercept or placebo in the parent protocol who shall continue into Long-term Post-treatment Follow-up Phase in the rollover study until the follow-up commitments are met (unless requirements are met as per parent protocol to crossover to luspatercept treatment).
4. Participant understands and voluntarily signs an informed consent document prior to any study-related assessments or procedures being conducted.
5. Participant demonstrates compliance, as assessed by the investigator, with the parent study protocol requirements.
6. Applies to on treatment Participants only- females of childbearing potential (FCBP) defined as a sexually mature woman who:
1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy or amenorrhea due to other medical reasons does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months) and must:
1. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the participant practices true abstinence* from heterosexual contact.
2. Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with highly effective, contraception without interruption, 35 days prior to starting investigational product (IP), during the study therapy (including dose interruptions), and for 84 days after discontinuation of study therapy.
7. Applies to on treatment participants only- Male participants must:
a. Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 84 days following investigational product discontinuation even if he has undergone a successful vasectomy.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
The presence of any of the following will exclude a participant from enrollment:
1. Applies to on treatment participants only- Concomitant use of any medications/procedures that are prohibited in the parent luspatercept protocol.
2. Participant has met one or more criteria for study discontinuation as stipulated in the parent luspatercept protocol.
3. Applies to on treatment participants only- More than 26 days between last luspatercept dose in the parent protocol and first dose into ACE-536-LTFU-001 protocol unless dose delay or dose discontinuation criteria met.
4. Applies to on treatment participants only- Pregnant or breastfeeding females.
5. Participant has any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that would prevent the subject from participating in the study.
6. Participant has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
7. Participant has any condition that confounds the ability to interpret data from the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/08/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
12/05/2028
Query!
Actual
Query!
Sample size
Target
665
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Local Institution - 100 - South Brisbane
Query!
Recruitment hospital [2]
0
0
Local Institution - 103 - Adelaide
Query!
Recruitment hospital [3]
0
0
Local Institution - 102 - Clayton
Query!
Recruitment hospital [4]
0
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment postcode(s) [1]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
2050 - Camperdown
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Tennessee
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Brasschaat
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Brugge
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Ghent
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Leuven
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Sofia
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Plovdiv
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Ontario
Query!
Country [18]
0
0
China
Query!
State/province [18]
0
0
Beijing
Query!
Country [19]
0
0
China
Query!
State/province [19]
0
0
Guangdong
Query!
Country [20]
0
0
China
Query!
State/province [20]
0
0
Shanghai
Query!
Country [21]
0
0
China
Query!
State/province [21]
0
0
Sichuan
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Tianjin
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Zhejiang
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Angers
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Creteil
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
La Tronche
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Lille
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Marseille Cedex 9
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Paris
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Pessac Cedex
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Pierre Benite cedex
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Strasbourg
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Toulouse Cedex 9
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Tours
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Berlin
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Dresden
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Duesseldorf
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Dusseldorf
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Halle
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Hamburg
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Hannover
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Leipzig
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Mainz
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
München
Query!
Country [45]
0
0
Greece
Query!
State/province [45]
0
0
Athens
Query!
Country [46]
0
0
Greece
Query!
State/province [46]
0
0
Rio Patras
Query!
Country [47]
0
0
Greece
Query!
State/province [47]
0
0
Thessaloniki
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Afula
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Haifa
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Jerusalem
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Nahariya
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Petah Tikva
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Toscana
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Allessandria
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Bologna
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Brindisi
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Cagliari
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Ferrara
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Genoa
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Lecce
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Milano
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Modena
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Napoli
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Orbassano
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Pavia
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Reggio Di Calabria
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Roma
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Rozzano
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Varese
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Verona
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Aichi
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Chiba
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Ehime
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Gifu
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Hyogo
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Ibaraki
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Kanagawa
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Miyagi
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Nagasaki
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Tokyo
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Kamakura
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Osaka
Query!
Country [83]
0
0
Lebanon
Query!
State/province [83]
0
0
Hazmieh
Query!
Country [84]
0
0
Malaysia
Query!
State/province [84]
0
0
Johor
Query!
Country [85]
0
0
Malaysia
Query!
State/province [85]
0
0
Kedah
Query!
Country [86]
0
0
Malaysia
Query!
State/province [86]
0
0
Perak
Query!
Country [87]
0
0
Malaysia
Query!
State/province [87]
0
0
Sabah
Query!
Country [88]
0
0
Malaysia
Query!
State/province [88]
0
0
Sarawak
Query!
Country [89]
0
0
Malaysia
Query!
State/province [89]
0
0
Wilayah Persekutuan Kuala Lumpur
Query!
Country [90]
0
0
Netherlands
Query!
State/province [90]
0
0
Amsterdam
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Barakaldo
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Barcelona
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Madrid
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Oviedo
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Salamanca
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Seville
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Valencia
Query!
Country [98]
0
0
Sweden
Query!
State/province [98]
0
0
Goteborg
Query!
Country [99]
0
0
Sweden
Query!
State/province [99]
0
0
Lund
Query!
Country [100]
0
0
Sweden
Query!
State/province [100]
0
0
Stockholm
Query!
Country [101]
0
0
Taiwan
Query!
State/province [101]
0
0
Kaohsiung, San Ming Dist.
Query!
Country [102]
0
0
Taiwan
Query!
State/province [102]
0
0
Taichung
Query!
Country [103]
0
0
Taiwan
Query!
State/province [103]
0
0
Taipei
Query!
Country [104]
0
0
Thailand
Query!
State/province [104]
0
0
Bangkok
Query!
Country [105]
0
0
Thailand
Query!
State/province [105]
0
0
Chiang Mai
Query!
Country [106]
0
0
Tunisia
Query!
State/province [106]
0
0
Sousse
Query!
Country [107]
0
0
Tunisia
Query!
State/province [107]
0
0
Tunis
Query!
Country [108]
0
0
Turkey
Query!
State/province [108]
0
0
Adana
Query!
Country [109]
0
0
Turkey
Query!
State/province [109]
0
0
Ankara
Query!
Country [110]
0
0
Turkey
Query!
State/province [110]
0
0
Istanbul
Query!
Country [111]
0
0
Turkey
Query!
State/province [111]
0
0
Izmir
Query!
Country [112]
0
0
Turkey
Query!
State/province [112]
0
0
Mersin
Query!
Country [113]
0
0
United Kingdom
Query!
State/province [113]
0
0
Aberdeen
Query!
Country [114]
0
0
United Kingdom
Query!
State/province [114]
0
0
Leeds
Query!
Country [115]
0
0
United Kingdom
Query!
State/province [115]
0
0
London
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Oxford
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Sutton in Ashfield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Celgene
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit from continuing treatment with luspatercept * Participants in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met * The study design is divided into the Transition Phase, Treatment Phase and Follow-up Phase. Participants will enter transition phase and depending on their background will enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU) phase * Transition Phase is defined as one Enrollment visit * Treatment Phase: For participants in luspatercept treatment the dose and schedule of luspatercept in this study will be the same as the last dose and schedule in the parent luspatercept study. This does not apply to participants that are in long-term follow-up from the parent protocol * Follow-up Phase includes: - 42 Day Safety Follow-up Visit * During the Safety Follow up, the participants will be followed for 42 days after the last dose of luspatercept, for the assessment of safety-related parameters and adverse event (AE) reporting - Long-term Post-treatment Follow-up (LTPTFU) Phase * Participants will be followed for overall survival every 6 months for at least 5 years from first dose of luspatercept in the parent protocol, or 3 years of post-treatment from last dose, whichever occurs later, or until death, withdrawal of consent, study termination, or until a subject is lost to follow-up. Participants will also be monitored for progression to AML or any malignancies/pre-malignancies. New anticancer or disease related therapies should be collected at the same time schedule Participants transitioning from a parent luspatercept study in post-treatment follow-up (safety or LTPTFU) will continue from the same equivalent point in this rollover study. The rollover study will be terminated, and relevant participants will discontinue from the study when all participants fulfill at least 5 years from the first dose of luspatercept in the parent protocol, or 3 years of post-treatment from last dose, whichever occurs later.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04064060
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
BMS Study Connect Contact Center www.BMSStudyConnect.com
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
855-907-3286
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
See Plan Description
Query!
Available to whom?
See Plan Description
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04064060